Treatment of hemorrhagic lupus pneumonitis with plasmapheresis

Erickson, Rich; Franklin, W.; Emlen, Woodruff

doi:10.1016/s0049-0172(05)80005-8

Cited by 78 publications

(40 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…iffuse pulmonary hemorrhage (DPH) is an infrequent but life-threatening complication in patients with systemic lupus erythematosus (SLE) (1); its prevalence ranges from ,2% to 5.4% (2)(3)(4) and the mortality rate ranges from 23% to 90% (2,5). Spontaneous developments can be rapidly unfavorable, with death occurring within the 48 h following the onset of the first symptoms.…”

mentioning

confidence: 99%

Pristane-Induced Granulocyte Recruitment Promotes Phenotypic Conversion of Macrophages and Protects against Diffuse Pulmonary Hemorrhage in Mac-1 Deficiency

Shi

Tsuboi

Furuhashi

et al. 2014

The Journal of Immunology

View full text Add to dashboard Cite

Diffuse pulmonary hemorrhage (DPH) is an uncommon but critical complication of systemic lupus erythematosus. Peritoneal administration of 2,6,10,14-tetramethylpentadecane (pristane) can recapitulate a lupus-like syndrome in mice, which can develop into DPH within a few weeks, especially in C57BL/6 mice. Mac-1 (CD11b/CD18), a leukocyte adhesion molecule, is known to play a role in inflammation by regulating migration of leukocytes into injured tissue. In this study, we aimed to clarify the role of Mac-1 in pristane-induced DPH, using Mac-1−/− and wild-type (WT) mice on a C57BL/6 background. After pristane injection, Mac-1−/− mice showed reduced prevalence of DPH and attenuated peritonitis compared with WT mice. Analysis of the peritoneal lavage on days 5 and 10 after pristane treatment revealed increased numbers of eosinophils and alternatively activated macrophages, but decreased numbers of neutrophils and classically activated macrophages in Mac-1−/− mice compared with WT. Enhanced production of IL-4 and IL-13, both key mediators of macrophage polarization toward the mannose receptor+ (MMR+) phenotype, was observed in the peritoneal cavity of Mac-1−/− mice. Depletion of neutrophils and eosinophils or adoptive transfer of classically activated macrophages resulted in the exacerbation of pristane-mediated DPH in both WT and Mac-1−/− mice. Moreover, peritoneal transfer of F4/80highMMR+ alternatively activated macrophages successfully reduced the prevalence of DPH in WT mice. Collectively, Mac-1 promoted acute inflammatory responses in the peritoneal cavity and the lungs by downregulating granulocyte migration and subsequent phenotypic conversion of macrophages in a pristane-induced systemic lupus erythematosus model.

show abstract

mentioning

confidence: 99%

Pristane-Induced Granulocyte Recruitment Promotes Phenotypic Conversion of Macrophages and Protects against Diffuse Pulmonary Hemorrhage in Mac-1 Deficiency

Shi

Tsuboi

Furuhashi

et al. 2014

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Its absolute indications include hyper viscosity, cryoglobulinemia, pulmonary hemorrhage and TTP. PP may be useful in cyclophosphamide resistant and serious organ-threatening disease [Erickson, 1994;Wallance, 2001]. It is safe in children and pregnant females [Wallance, 2001].…”

Section: Plasmapheresis (Pp)mentioning

confidence: 99%

Management of Pregnant Lupus

Alosaimi¹,

Yelamanchili²

2012

Systemic Lupus Erythematosus

View full text Add to dashboard Cite

“…( Badsha et al, 2004;Eagen et al, 1978;Zamora et al, 1997) Its prevalence among SLE patients ranges between <2% and 5.4 % (Santos-Ocampo et al, 2000;Zamora et al, 1997), and the mortality rate ranges between 50% to 90%. ( Erickson et al, 1994;Schwab et al, 1993) Usually it occurs in established disease, especially with lupus nephritis. (Zamora et al, 1997) Other extrapulmonary manifestations occur with variable degree.…”

Section: Diffuse Alveolar Hemorrhagementioning

confidence: 99%

“…(Schwab et al, 1993a;Swigris et al, 2008) DAH is one of the few indications where plasmapharesis has been shown to be effective, especially in refractory cases. (Erickson et al, 1994;Santos-Ocampo et al, 2000) Plasmapharesis may improve survival in patients who failed treatment with high dose steroids and cyclophosphamide. (Erickson et al, 1994) More recently rituximab has been used in refractory cases with promising results.…”

Section: Diffuse Alveolar Hemorrhagementioning

confidence: 99%

“…(Erickson et al, 1994;Santos-Ocampo et al, 2000) Plasmapharesis may improve survival in patients who failed treatment with high dose steroids and cyclophosphamide. (Erickson et al, 1994) More recently rituximab has been used in refractory cases with promising results. (Pottier et al, 2011) The mean duration of alveolar hemorrhage from onset to radiographic resolution is 7.8 days.…”

Section: Diffuse Alveolar Hemorrhagementioning

confidence: 99%

See 1 more Smart Citation